NASDAQ:IMMUImmunomedics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immunomedics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.64 +1.21 (+6.57 %) (As of 04/10/2020 04:27 AM ET) Add Compare Share Today's Range$18.35Now: $19.64▼$20.4450-Day Range$9.40MA: $14.26▼$18.9152-Week Range$8.80Now: $19.64▼$22.22Volume7.06 million shsAverage Volume3.34 million shsMarket Capitalization$4.20 billionP/E RatioN/ADividend YieldN/ABeta2.34 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingImmunomedics has received a consensus rating of Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.55, Immunomedics has a potential upside of 30.1% from its current price of $19.64.Amount of Analyst CoverageImmunomedics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.4 Community Rank Outperform VotesImmunomedics has received 420 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmunomedics has received 451 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmunomedics has received 51.78% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote “Outperform” if you believe IMMU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmunomedics does not currently pay a dividend.Dividend GrowthImmunomedics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunomedics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.40% of the stock of Immunomedics is held by insiders.Percentage Held by Institutions77.11% of the stock of Immunomedics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunomedics are expected to decrease by -40.36% in the coming year, from ($1.66) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunomedics is -10.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunomedics is -10.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunomedics has a P/B Ratio of 14.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMMU Previous Symbol CUSIP45290710 CIK722830 Webhttp://www.immunomedics.com/ Phone973-605-8200Debt Debt-to-Equity RatioN/A Current Ratio8.90 Quick Ratio8.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$290,000.00 Price / Sales14,488.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book14.23Profitability EPS (Most Recent Fiscal Year)($1.84) Net Income$-357,190,000.00 Net MarginsN/A Return on Equity-243.42% Return on Assets-69.84%Miscellaneous Employees346 Outstanding Shares213,930,000Market Cap$4.20 billion Next Earnings Date5/27/2020 (Estimated) OptionableOptionable Receive IMMU News and Ratings via Email Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IMMU Rates by TradingView Immunomedics (NASDAQ:IMMU) Frequently Asked Questions How has Immunomedics' stock been impacted by COVID-19 (Coronavirus)? Immunomedics' stock was trading at $13.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IMMU stock has increased by 46.8% and is now trading at $19.64. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Immunomedics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Immunomedics. When is Immunomedics' next earnings date? Immunomedics is scheduled to release its next quarterly earnings announcement on Wednesday, May 27th 2020. View our earnings forecast for Immunomedics. How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.05. The biopharmaceutical company had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.18 million. During the same quarter in the prior year, the firm posted ($0.68) earnings per share. View Immunomedics' earnings history. What price target have analysts set for IMMU? 10 equities research analysts have issued 12-month target prices for Immunomedics' stock. Their forecasts range from $5.00 to $34.00. On average, they anticipate Immunomedics' stock price to reach $25.55 in the next year. This suggests a possible upside of 30.1% from the stock's current price. View analysts' price targets for Immunomedics. What are Wall Street analysts saying about Immunomedics stock? Here are some recent quotes from research analysts about Immunomedics stock: 1. According to Zacks Investment Research, "Immunomedics posted a wider-than-expected loss in the fourth quarter of 2019. The regulatory application for the company’s lead product candidate, sacituzumab govitecan, as a third-line therapy for metastatic breast cancer has been re-filed and accepted by the FDA. If approved, the candidate will be the first product to generate revenues for the company. In addition to breast and urothelial cancers, Immunomedics is also conducting studies on sacituzumab in other cancer types. The company intends to maximize the global commercial potential of sacituzumab govitecan, while accelerating its development as a single agent and in combination with checkpoint inhibitors across a number of clinical settings. The successful development of the candidate be a boost for the company. However, the company has no approved product yet, which is a concern." (3/3/2020) 2. HC Wainwright analysts commented, "We remind investors that sacituzumab previously achieved a 31% 6.8-month median progression-free survival (mPFS) which, in our view, compares favorably to chemotherapy’s effect in this patient population (10-13% ORR and 3-4 month mPFS). Accordingly, we reiterate our Buy rating, while reducing our 12-month price target from $28 to $26 to account for the removal of the second- line HR+, HER2- mBC setting from our assumptions. IMMU-132 filing resubmission remains on track for early 4Q19." (8/8/2019) Has Immunomedics been receiving favorable news coverage? Press coverage about IMMU stock has trended very negative this week, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Immunomedics earned a news impact score of -3.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutImmunomedics. Who are some of Immunomedics' key competitors? Some companies that are related to Immunomedics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Immunomedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Celgene (CELG), Synergy Pharmaceuticals (SGYP), Seattle Genetics (SGEN), NVIDIA (NVDA), ImmunoGen (IMGN), Micron Technology (MU), Exelixis (EXEL), Iovance Biotherapeutics (IOVA), Netflix (NFLX) and Novavax (NVAX). Who are Immunomedics' key executives? Immunomedics' management team includes the following people: Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)Mr. Scott A. Canute MBA, Exec. Director (Age 58)Mr. Brendan Delaney, Chief Commercial Officer (Age 44)Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52) What is Immunomedics' stock symbol? Immunomedics trades on the NASDAQ under the ticker symbol "IMMU." How do I buy shares of Immunomedics? Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Immunomedics' stock price today? One share of IMMU stock can currently be purchased for approximately $19.64. How big of a company is Immunomedics? Immunomedics has a market capitalization of $4.20 billion and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-357,190,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Immunomedics employs 346 workers across the globe. View additional information about Immunomedics. What is Immunomedics' official website? The official website for Immunomedics is http://www.immunomedics.com/. How can I contact Immunomedics? Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: Why do commodities matter?
